Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. The Company applys purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Its portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference.

Company profile
Ticker
TFX
Exchange
Website
CEO
Liam Kelly
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
1902 Federal Road, LLC • Arrow Internacional de Chihuahua, S.A. de C.V. • Arrow Internacional de Mexico, S.A. de C.V. • Arrow International • Arrow Interventional, Inc. • Distribuidora Arrow, S.A. de C.V. • Essential Medical LLC • Hudson Respiratory Care Tecate, S. de R.L. de C.V. • ICOR AB • Inmed Manufacturing ...
IRS number
231147939
TFX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
SD
Conflict minerals disclosure
26 May 23
8-K
Amendments to Articles of Incorporation or Bylaws
11 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Teleflex Reports First Quarter Financial Results and Full Year 2023 Outlook
4 May 23
ARS
2022 FY
Annual report to shareholders
14 Apr 23
DEF 14A
Definitive proxy
31 Mar 23
8-K
Other Events
24 Mar 23
PRE 14A
Preliminary proxy
10 Mar 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Teleflex Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 23
Transcripts
TFX
Earnings call transcript
2022 Q4
23 Feb 23
TFX
Earnings call transcript
2022 Q3
27 Oct 22
TFX
Earnings call transcript
2022 Q2
28 Jul 22
TFX
Earnings call transcript
2022 Q1
28 Apr 22
TFX
Earnings call transcript
2021 Q4
24 Feb 22
TFX
Earnings call transcript
2021 Q3
28 Oct 21
TFX
Earnings call transcript
2021 Q2
29 Jul 21
TFX
Earnings call transcript
2021 Q1
2 May 21
TFX
Earnings call transcript
2020 Q4
28 Feb 21
TFX
Earnings call transcript
2020 Q3
2 Nov 20
Latest ownership filings
4
Jaewon Ryu
11 May 23
4
STUART A RANDLE
11 May 23
4
Neena M Patil
11 May 23
4
Andrew A Krakauer
11 May 23
4
Stephen K. M.D. Klasko
11 May 23
4
JOHN C HEINMILLER
11 May 23
4
GRETCHEN R HAGGERTY
11 May 23
4
Candace H Duncan
11 May 23
3
Jaewon Ryu
11 May 23
144
Notice of proposed sale of securities
10 May 23
Financial summary
Quarter (USD) | Apr 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 264.14 mm | 264.14 mm | 264.14 mm | 264.14 mm | 264.14 mm | 264.14 mm |
Cash burn (monthly) | 9.30 mm | 16.88 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 20.75 mm | 37.66 mm | n/a | n/a | n/a | n/a |
Cash remaining | 243.39 mm | 226.48 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 26.2 | 13.4 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2023
97.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 470 |
Opened positions | 56 |
Closed positions | 57 |
Increased positions | 183 |
Reduced positions | 143 |
13F shares | Current |
---|---|
Total value | 11.56 tn |
Total shares | 45.68 mm |
Total puts | 20.40 k |
Total calls | 42.10 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
T. Rowe Price Investment Management | 8.56 mm | $2.17 tn |
Vanguard | 5.45 mm | $1.38 tn |
BLK Blackrock | 3.98 mm | $1.01 tn |
Wellington Management | 3.10 mm | $785.39 bn |
JHG Janus Henderson | 3.10 mm | $785.25 bn |
MS Morgan Stanley | 2.89 mm | $732.49 bn |
STT State Street | 2.33 mm | $589.95 bn |
T. Rowe Price | 1.83 mm | $464.52 bn |
Geode Capital Management | 971.68 k | $245.58 bn |
Allspring Global Investments | 844.50 k | $213.92 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 May 23 | Duncan Candace H | Common Stock | Grant | Acquire A | No | No | 0 | 527 | 0.00 | 4,041.252 |
9 May 23 | Duncan Candace H | Stock Option / Common Stock | Grant | Acquire A | No | No | 251.99 | 1,076 | 271.14 k | 1,076 |
9 May 23 | Gretchen R Haggerty | Common Stock | Grant | Acquire A | No | No | 0 | 527 | 0.00 | 4,105 |
9 May 23 | Gretchen R Haggerty | Stock Option / Common Stock | Grant | Acquire A | No | No | 251.99 | 1,076 | 271.14 k | 1,076 |
9 May 23 | Heinmiller John C | Common Stock | Grant | Acquire A | No | No | 0 | 527 | 0.00 | 2,476 |
9 May 23 | Heinmiller John C | Stock Option / Common Stock | Grant | Acquire A | No | No | 251.99 | 1,076 | 271.14 k | 1,076 |
9 May 23 | Klasko Stephen K. M.D. | Common Stock | Grant | Acquire A | No | No | 0 | 681 | 0.00 | 4,563.462 |
9 May 23 | Klasko Stephen K. M.D. | Stock Option / Common Stock | Grant | Acquire A | No | No | 251.99 | 1,076 | 271.14 k | 1,076 |
9 May 23 | Krakauer Andrew A | Common Stock | Grant | Acquire A | No | No | 0 | 527 | 0.00 | 4,471.577 |
9 May 23 | Krakauer Andrew A | Stock Option / Common Stock | Grant | Acquire A | No | No | 251.99 | 1,076 | 271.14 k | 1,076 |
News
Teleflex Secures FDA Clearance For Wattson Temporary Pacing Guidewire
7 Jun 23
Teleflex Says Arrow EZ-IO Needle Is The First And Only Intraosseous (IO) Needle To Receive 510(k) clearance From FDA For MR Conditional Labeling
6 Jun 23
Teleflex Secures Two Group Purchasing Agreements With Premier, Inc.
1 Jun 23
CL King Initiates Coverage On Teleflex with Buy Rating, Announces Price Target of $293
30 May 23
Expert Ratings for Teleflex
30 May 23
Press releases
Teleflex Receives FDA Clearance for the Wattson® Temporary Pacing Guidewire
7 Jun 23
Teleflex Announces the Arrow® EZ-IO® Needle Is Now FDA Cleared For Use in an MRI Environment
6 Jun 23
Teleflex Awarded Agreements with Premier, Inc.
1 Jun 23
INVESTOR NOTICE - Andrews & Springer LLC Is Investigating Teleflex Incorporated For Potential Securities Fraud Violations and Breaches of Fiduciary Duty - TFX
22 May 23
SHAREHOLDER NOTICE - Andrews & Springer LLC Is Investigating Teleflex Incorporated For Potential Securities Violations and Breaches of Fiduciary Duty - TFX
15 May 23